CommercialGilead Explores Triple-Target T-Cell Engagers in over $1.5B Merus...

Gilead Explores Triple-Target T-Cell Engagers in over $1.5B Merus Partnership

-

Bispecific T-cell engagers are gaining prominence in oncology, yet this hasn’t deterred a pharmaceutical collaboration from exploring the next phase of this treatment approach. Gilead and Merus have joined forces in a partnership exceeding $1.5 billion to investigate trispecific T-cell engagers, as recently announced. Under this agreement, Merus will lead early-stage research on two programs, with the potential for a third, in exchange for an initial payment of $56 million and a $25 million equity investment from Gilead.

Gilead will assess the possibility of licensing any of these programs upon reaching specified research milestones. Following this, Gilead will take over responsibility for further development and commercialization. Merus stands to receive up to $1.5 billion in milestone payments across all potential programs and has the option to opt for a 50-50 profit-sharing arrangement for the third program instead of milestone payments.

Dr. Flavius Martin, Gilead’s EVP and head of research, expressed excitement for the development of additional multispecific antibodies capable of eliciting robust anti-tumor immune responses with improved efficacy and safety profiles.

Bispecific T-cell engagers have emerged as promising cancer therapies, particularly in addressing small cell lung cancer, where breakthroughs have been limited. Among larger pharmaceutical companies, Amgen has been at the forefront with its BiTE platform and associated candidates such as the FDA-approved Blincyto and tarlatamab in clinical stages. Merck & Co. has also made significant investments, acquiring Harpoon Therapeutics for $680 million.

While Gilead currently has a phase 1-stage bispecific T-cell engager in its pipeline, intended for HIV treatment rather than cancer, the company is now broadening its focus.

Both Gilead and Merus are seeking to overcome recent safety concerns in their oncology endeavors. Merus faced a share price decline in December following the disclosure of three deaths in an open-label phase 1/2 study of MCLA-129 for lung cancer treatment. Despite promising disease control rates, particularly in combination with AstraZeneca’s Tagrisso in first-line settings, safety issues emerged.

Meanwhile, Gilead’s CD47 drug magrolimab has encountered challenges. The company recently discontinued its development as a blood cancer treatment due to reported deaths and has paused solid tumor trials following a partial FDA hold. Gilead is currently reassessing the risk-benefit profile across all affected studies.

Latest news

Top 10 Risks Associated With Pharmaceutical Raw Material Sourcing

Executive Summary Pharmaceutical raw material sourcing directly influences product quality, manufacturing continuity, regulatory compliance, and commercial performance. Active pharmaceutical ingredients...

Bristol Myers Squibb Combines Research and Development Under Cristian Massacesi

Bristol Myers Squibb (BMS) will consolidate its research and development operations into a single organization under the leadership of...

Regeneron reports encouraging phase 2 results for baloncibart in a crucial trial for nervous system disorders and eyes

Regeneron has posted positive phase 2 data on baloncibart in postural orthostatic tachycardia syndrome (POTS), teeing the biotech up...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you